340 related articles for article (PubMed ID: 25523155)
1. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
2. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study.
Bekos C; Grimm C; Brodowicz T; Petru E; Hefler L; Reimer D; Koch H; Reinthaller A; Polterauer S; Polterauer M
Sci Rep; 2017 Nov; 7(1):14474. PubMed ID: 29101329
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma.
Schwameis R; Grimm C; Petru E; Natter C; Staudigl C; Lamm W; Koelbl H; Krainer M; Brodowicz T; Reinthaller A; Polterauer S
PLoS One; 2015; 10(8):e0133838. PubMed ID: 26248232
[TBL] [Abstract][Full Text] [Related]
5. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic characteristics and prognosis factors of uterine sarcomas in central Tunisia].
Khlifi A; Fathallah K; Zbidi C; Hidar S; Bibi M; Khairi H
Bull Cancer; 2014; 101(7-8):669-80. PubMed ID: 25091649
[TBL] [Abstract][Full Text] [Related]
8. Uterine leiomyosarcoma: an updated series.
Rauh-Hain JA; Oduyebo T; Diver EJ; Guseh SH; George S; Muto MG; del Carmen MG
Int J Gynecol Cancer; 2013 Jul; 23(6):1036-43. PubMed ID: 23714705
[TBL] [Abstract][Full Text] [Related]
9. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P
Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626
[TBL] [Abstract][Full Text] [Related]
10. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
[TBL] [Abstract][Full Text] [Related]
11. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas.
Wolfson AH; Wolfson DJ; Sittler SY; Breton L; Markoe AM; Schwade JG; Houdek PV; Averette HE; Sevin BU; Penalver M
Gynecol Oncol; 1994 Jan; 52(1):56-62. PubMed ID: 8307502
[TBL] [Abstract][Full Text] [Related]
12. Uterine sarcoma: prognostic factors and treatment evaluation.
Naaman Y; Shveiky D; Ben-Shachar I; Shushan A; Mejia-Gomez J; Benshushan A
Isr Med Assoc J; 2011 Feb; 13(2):76-9. PubMed ID: 21443030
[TBL] [Abstract][Full Text] [Related]
13. Leiomyosarcoma of the uterus. A 50-year review of 42 cases.
Bartsich EG; Bowe ET; Moore JG
Obstet Gynecol; 1968 Jul; 32(1):101-6. PubMed ID: 5742081
[No Abstract] [Full Text] [Related]
14. [Histopathological, clinical and prognostic aspects of smooth-muscle tumors of the uterus (cellular myoma, leiomyosarcoma, endometrial stromal sarcoma)].
De Giacomo G; Palla G; Paparatti L; Villani L; Moneta E
Minerva Ginecol; 1988 Feb; 40(2):73-81. PubMed ID: 3399122
[No Abstract] [Full Text] [Related]
15. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
[TBL] [Abstract][Full Text] [Related]
16. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.
Raut CP; Nucci MR; Wang Q; Manola J; Bertagnolli MM; Demetri GD; Morgan JA; Muto MG; Fletcher CD; George S
Eur J Cancer; 2009 Nov; 45(16):2818-24. PubMed ID: 19647426
[TBL] [Abstract][Full Text] [Related]
18. Literature review of outcomes and prevalence and case report of leiomyosarcomas and non-typical uterine smooth muscle leiomyoma tumors treated with uterine artery embolization.
Kainsbak J; Hansen ES; Dueholm M
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():130-7. PubMed ID: 26117442
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
[TBL] [Abstract][Full Text] [Related]
20. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]